Medtronic raises annual sales growth forecast on heart devices demand
By Kamal Choudhury and Christy Santhosh
Nov 18 (Reuters) - Medtronic MDT.N beat second-quarter estimates and raised annual sales growth forecast on Tuesday, driven by strong demand for heart devices, sending its shares up nearly 5%.
Investor expectations for medical device makers have remained high in recent quarters, boosted by robust demand for surgical procedures, particularly among older adults, greater physician adoption and advances in technology.
Sales in Medtronic's cardiovascular segment jumped 10.8% to $3.44 billion during the quarter, powered by its pulsed field ablation (PFA) portfolio used to treat irregular heart rhythms.
Bernstein analyst Christian Moore said Medtronic's growth in PFA suggests "sequential share-taking" from Boston Scientific, which is key to the bull thesis for the medical device maker.
Peers Boston Scientific BSX.N and Edwards Lifesciences EW.N also beat quarterly expectations last month, buoyed by resilient demand for heart devices.
Medtronic is very focused on tuck-in M&A deals, particularly in cardiology and neuroscience, with a preference for companies that are "early stage or close to market", CEO Geoff Martha said on a call with analysts.
Finance chief Thierry Pieton told Reuters the company is "on track" with the separation of its diabetes business and expects the unit, which houses insulin pumps and other wearable devices, to go public in the first half of 2026.
Medtronic's adjusted earnings per share of $1.36 beat analysts' estimate of $1.31, according to data compiled by LSEG. Revenue of $8.96 billion was also above expectations of $8.87 billion.
Martha said the company was well positioned for even greater acceleration of revenue growth in the back half of the year and beyond.
The company raised the lower end of fiscal 2026 adjusted profit forecast to $5.62 per share from $5.60, while keeping the top end intact at $5.66. This includes a potential hit of about $185 million from tariffs, unchanged from its prior expectation.
It also increased its full-year organic revenue growth forecast to about 5.5%, from around 5% projected earlier.
Medtronic's cardiovascular unit sales vs total sales Medtronic's cardiovascular unit sales vs total sales
Related Articles
Will the Bank of England Continue Rate Cuts? What's the Pound's Trajectory in 2026?
TradingKey - GBP/USD has shown strong performance over the past month, rising from around 1.30 to 1.34, and has not declined despite expectations of a central bank rate cut. Looking ahead to 2026, GBP/USD may experience volatile pullbacks, testing support levels around 1.25.
U.S. November CPI: How Will Inflation Fluctuations Transmit to US Stocks? Tariffs Are the Key!
TradingKey - It should be emphasised that tariff policy is the core driver sustaining the current high level of inflation,...Under the combined influence of tariffs and inflation, the U.S. stock market will probably follow a down-then-up trend in 2026.
Japan Central Bank Rate Hike To Three-Decade High Imminent, How Will The Market Go? Which Assets Most Affected?
As global monetary policy divergence enters a critical phase, the Bank of Japan (BoJ) is anticipated to raise its benchmark interest rate at the monetary policy meeting on December 19, 2025, by 25 basis points to 0.75% , marking its highest level in nearly 30 years.
Bitcoin Stocks 2025 Collective Plunge, Still Worth Investing in Future?
Bitcoin stocks involved in trading operations outperformed mining stocks and DAT-category stocks, thus warranting greater priority attention. If Bitcoin's future price trend indeed aligns with Grayscale's projection, Bitcoin stock prices are also expected to rebound and even reach new highs.
Gold Price Steady Climb and the Sudden Surge of Silver and Copper: Will Their Bull Run Extend Into 2026?
Dow Jones Market Data shows this marks the first time since 1980all three metals—gold, silver, and copper—simultaneously refreshed their all-time highs in the same year. Will this rally extend into 2026?
